The FDA has approved an over-the-counter (OTC) 0.025% ophthalmic formulation of the selective alpha₂-adrenergic agonist brimonidine tartrate (Lumify – Bausch & Lomb) for treatment of ocular redness in adults and children ≥5 years old. Lumify is the first brimonidine product to be approved for OTC use.

PRESCRIPTION BRIMONIDINE PRODUCTS ― Brimonidine is available by prescription in higher-strength formulations both alone (Alphagan-P, and others) and in combinations with the beta blocker timolol (Combigan) and the carbonic anhydrase inhibitor brinzolamide (Simbrinza)1 for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Brimonidine is also available by prescription in a topical gel formulation (Mirvaso) for treatment of the facial erythema of ... more      

Would you like to read the rest of this article?  Gain access below.